Clarity Pharmaceuticals (ASX:CU6) signed a commercial manufacturing agreement with SpectronRx for its diagnostic product, 64Cu-SAR-bisPSMA, according to a Tuesday filing with the Australian bourse.
SpectronRx's Indiana facility will offer on-demand commercial-scale manufacturing of copper-64 and 64Cu-SAR-bisPSMA, enabling distribution to all 50 states, the filing said.
The agreement allows for expansion into additional sites, increasing the manufacturing capacity of patient-ready doses of 64Cu-SAR-bisPSMA in US regional hubs, per the filing.
Shares rose 5% in midday trade on Tuesday.